












Future directions of vaginally administered 
HIV microbicide formulations
By Dr Christopher McConville
future directions in medication delivery
Human Immunodeficiency Virus (HIV) 
is a retrovirus that can result in rare 
opportunistic infections occurring in 
humans. The onset of these infections 
is known as Acquired Immune 
Deficiency Syndrome (AIDS). The 
major modes of HIV transmission are 
sexual contact, exposure to infected 
blood, infected needles and mother-
to-child. Heterosexual transmission 
is responsible for the majority of 
infections,1 resulting in transmission 
of HIV due to infected semen or 
vaginal and cervical secretions 
containing infected lymphocytes.2 HIV 
destroys the human immune system 
leaving the body susceptible to 
opportunistic infections, which lead to 
the onset of AIDS.
In the absence of an HIV vaccine 
there is a clear rationale for the use of 
alternative strategies to prevent HIV 
infection. Vaginal HIV microbicides 
are formulations of chemical or 
biological agents that when delivered 
to the vagina destroy or inhibit HIV. 
The ideal vaginal HIV microbicide 
must have activity against cell-free 
and cell-associated HIV, it must not 
cause damage to the tissue or flora 
of the vagina, it must be retained in 
the vagina, act locally and retain its 
activity in the presence of semen and 
across a broad pH range.3
There are various mechanisms by 
which vaginal HIV microbicides 
prevent HIV infection: 
1. by destroying the virus as soon as 
it enters the vagina; 
2. maintenance of the vaginal flora, 
which provides a protective 
vaginal pH; 
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3. prevention of HIV binding to CD4 
receptors; 
4. by preventing the HIV replication 
process;
5. by providing a physical barrier that 
prevents HIV from entering the 
vaginal mucosa; and 
6. by prevention of sexually 
transmitted infections (STIs), which 
may increase the possibility of 
HIV infection. 
HIV microbicides that 
destroy the virus on entry 
to the vagina
To date a number of HIV microbicidal 
products have been unsuccessfully 
tested in human clinical trials. For 
example nonoynol-9 (N-9), which is 
a non-ionic surfactant that destroys 
viruses and bacteria by disrupting 
their membrane, was the first HIV 
microbicide to be tested. It was shown 
to destroy HIV in vitro4 and prevent 
Simian Immunodeficiency Virus (SIV) 
transmission in macaques.5 However a 
vaginal gel containing 52.5 mg of N-9 
was evaluated in a phase 2/3 trial at 
four international sites and was found 
to enhance the transmission of HIV 
due to the surfactant characteristics of 
N-9 damaging the vaginal epithelium.6 
Another surfactant based microbicide, 
C31G, was shown to have a greater 
efficacy against cell-free and cell-
associated HIV when compared to 
N-9.7 A phase 1 clinical trial of C31G 
confirmed that a 1.0% C31G gel 
formulation resulted in less irritation 
when compared to higher doses of 
C31G and nonoxynol-9.8–9 A phase 3, 
double-blind, randomised, placebo 
controlled trial in Ghana resulted in a 
1.0% C31G gel (SAVVY) showing no 
association with an increase in HIV 
transmission. The trial was unable 
to conclude if SAVVY was effective 
at preventing HIV infection when 
compared to a placebo.10 Another 
randomised phase III clinical trial in 
Nigeria concluded that SAVVY did 
not significantly reduce the incidence 
of HIV infection; in fact, the risk of 
infection was higher in the SAVVY 
group compared to the placebo group.11
HIV microbicides that 
maintain vaginal flora 
and pH
Given that normal vaginal pH is 
detrimental to viruses and bacteria, 
a viable microbicide strategy is the 
maintenance of vaginal pH in the 
presence of semen. Several products 
are being tested in humans. Acidform 
is a buffering gel formulation that 
not only maintains a low pH in the 
vagina, thereby maintaining a hostile 
environment to HIV, but also acts 
as a spermicidal agent.12 A phase 
I clinical trial demonstrated that 
Acidform caused no irritation to the 
vaginal epithelium. However when 
2.5 and 5.0% nonoxynol-9 where 
added to the Acidform formulation 
irritation and abrasions were seen 
in half of the women after two days 
and all the women after seven days.12 
BufferGel is another gel formulation 
that has been evaluated as a potential 
HIV microbicide. Like Acidform, it 
maintains vaginal pH between 3.8 
and 4.0 in the presence of semen.13 
A phase 1 clinical trial demonstrated 
that BufferGel is safe and well 
tolerated, and causes no damage 
to the vaginal epithelium.14 A phase 
2/2B, four-arm, randomised, placebo-
controlled trial demonstrated that 
BufferGel did reduce the risk of HIV 
infection in women.15
Vol. 30 – February #02
155
future directions in medication delivery
HIV microbicides 
inhibiting cell fusion 
and entry
Cell fusion and entry-inhibiting 
microbicides have a broad range of 
activity against sexually transmitted 
pathogens including HIV. They act by 
blocking the CD4-gp120 interaction 
between the virus and host cell.
PRO2000 was shown to be capable 
of blocking CD4-gp120 binding at 
nanomolar concentrations16 and that 
a PRO200 gel formulation provided 
100% protection in a mouse model 
when applied immediately before viral 
inoculation.17 However, this fell to 58% 
protection when the gel was applied 
30 minutes before viral inoculation, 
demonstrating the importance of 
timing of application of coitally 
dependent microbicides. A number of 
safety studies have been performed 
on PRO2000 gels (0.5–4.0% w/w) in 
sexually inactive HIV-positive women, 
and sexually active and sexually 
inactive HIV-negative women.18–20 
The studies confirmed that the gels 
were safe, although adverse effects 
were noted with a 4% gel. A Phase 
II/III trial of PRO2000 showed a 30% 
reduction in HIV infection in women 
who used PRO2000 gel immediately 
before intercourse.15
Carraguard is a microbicide gel 
formulation containing a 3% loading of 
carrageenan. Two phase I safety trials 
performed in HIV-negative sexually 
inactive women confirmed no signs 
of lesions or abrasions on the vaginal 
tissue.21–22 A phase II trial proved 
Carraguard to be safe for use over a 
period of one year.23 A phase III clinical 
trial did not prove Carraguard to be 
effective against male-to-female HIV 
transmission, with 134 new infections 
seen in the Carraguard group and 151 
new infections in the placebo group.24
Cellulose sulphate is believed to 
inhibit HIV infection by either binding 
to the target cell or by binding to 
the virus, thus preventing cell fusion 
and entry.25 Following testing in HIV-
negative sexually inactive women it 
has been proven to be safe with no 
serious adverse effects reported.26 
A phase III clinical trial of cellulose 
sulphate was stopped in January 
2007 after it was shown to have no 
effect on preventing HIV infection 





Reverse transcriptase inhibitors 
(RTIs), which inhibit the viral encoded 
enzyme reverse transcriptase 
responsible for the conversion of 
single strand viral RNA into double 
stranded DNA, are being evaluated 
as HIV microbicides. Antiretrovirals 
are currently used for the treatment 
of HIV in a combinational therapy 
known as Highly Active Antiretroviral 
Therapy (HAART). Both nucleotide and 
non-nucleoside reverse transcriptase 
inhibitors (NNRTIs) are under 
evaluation. NRTIs inhibit the process 
of reverse transcriptase by insertion 
into the propagating viral DNA, 
thereby inhibiting further synthesis 
of DNA. NNRTIs inhibit reverse 
transcriptase by binding directly to 
the reverse transcriptase enzyme and 
inhibiting the conversion of viral RNA 
into viral DNA.
Dapivirine (TMC120) is an NNRTI 
with high potency against HIV-1 (IC50 
value of 0.9). A phase I/II trial of orally 
administered dapivirine in HIV-positive 
patients showed a decrease in the 
viral load in these patients, without 
any adverse effects.8 A randomised, 
double-blind, placebo controlled phase 
I/II clinical trial demonstrated that 
twice daily administration of dapivirine 
loaded gels for 42 days was safe and 
well tolerated.29 Tenofovir (PMPA) 
is a NNRTI that is phosphorylated 
by adenylate kinase to tenofovir 
diphosphate, which in turn competes 
with deoxyadeosine 5’-triphosphate 
for incorporation into newly 
synthesised DNA. Once incorporated, 
tenofovir diphosphate results in 
chain termination, thus inhibiting 
viral replication. 
It has been demonstrated that there 
is less chance of HIV developing 
resistance to Tenofovir compared 
to other reverse transcriptase 
inhibitors.30 A phase I clinical trial 
of 0.3% and 1% Tenofovir vaginal 
gels in sexually active and sexually 
inactive HIV-negative and HIV-
positive women was found to be 
safe, acceptable and well tolerated 
for a two week twice daily course.31 
A recent phase IIb study of a 1% w/w 
Tenofovir gel has established the long-
awaited proof-of-concept for the HIV 
vaginal microbicide principle.32 For 
women reporting greater than 80% 
adherence to the gel regimen (two 
gel doses, one before and one after 
intercourse), a 54% reduction in HIV 
infections was reported. Protection 
rates decreased to 38% protection 
for 50–80% adherence and to 28% 
with less than 50% adherence. These 
results unequivocally demonstrate 
the importance of adherence on 
microbicide efficacy and suggest that 
use of a product which increases 
adherence may provide better 
protection. Various clinical studies 
have reported high levels of adherence 
and acceptability for commercial 
vaginal rings, particularly compared 
with gel formulations.33
HIV microbicide releasing 
vaginal rings
The vaginal ring is a flexible, torus-
shaped drug delivery device capable 
of delivering one or more drugs to 
the vagina in a sustained fashion 
(Figure 1). It is inserted into the vagina 
for up to twelve months at a time, 
where it slowly releases one or more 
drugs to provide either a local or 
systemic effect. Measuring between 
5 and 9.5 mm in cross-sectional 
diameter and between 50 and 75 mm 
in overall diameter, the rings have, 
to date, been primarily developed for 
the systemic delivery of contraceptive 
steroids and the localised and 
systemic delivery of steroids for 
hormone replacement therapy. 
The vaginal ring overcomes many of 
the disadvantages associated with 
more traditional vaginal drug dosage 
forms, such as gels, tablets and 
pessaries, which are often messy, 
interfere with intercourse and are 
poorly retained within the vagina. 
However, the major advantage of 
the IVR is its ability and versatility 
in providing long-term, continuous 
release of drug(s) at constant pre-
determined rates, thereby increasing 














cost-effectiveness, patient compliance 
and therapeutic efficacy. Furthermore 
the vaginal ring is user controlled and 
thus doesn’t require minor surgery or 
a physician for it to be placed in the 
vagina. There are two main types of 
vaginal rings available, the matrix and 
the reservoir vaginal rings.
The matrix ring is the simplest form 
of vaginal ring (Figure 2a). The drug is 
homogonously dispersed throughout 
the ring and results in the release rate 
being proportional to the drug loading 
and the surface area of the ring. The 
rings are manufactured in a single 
step, where the silicone, with the drug 
homogonously spread throughout it, 
is injected into a mould and allowed to 
cure at elevated temperatures.
During in vitro drug release from 
these matrix vaginal rings, the whole 
surface area of the ring is exposed 
to the dissolution medium and drug 
release occurs in several distinct 
stages. Firstly, drug molecules within 
the immobilised drug particles present 
at the surface of the ring dissociate 
from the crystal lattice and dissolve 
into the release medium, thus giving 
rise to a burst effect and creating 
a concentration gradient within the 
vaginal ring that thermodynamically 
drives the release process. Drug 
molecules near the ring surface then 
diffuse through the polymer and are 
subsequently released. 
As drug release continues, a drug 
depletion zone is created which 
separates the drug deficient surface 
from the inner drug loaded region of 
the polymer matrix. (It is also likely 
that water is able to penetrate into the 
channels created by drug depletion 
and, thus, dissolve the drug present 
at the depletion boundary.) The 
surface area of this inward moving 
depletion boundary decreases, 
with simultaneous increase in the 
thickness of the drug-depleted 
zone. Therefore, the amount of drug 
released decreases with time as 
the drug close to the surface of the 
ring becomes exhausted and the 
diffusional pathway for the remaining 
drug increases (Figure 3a). The in vitro 
release of drug from a matrix vaginal 
ring under sink conditions is described 
by the Higuchi equation (Equation 1),34 
a polymer matrix diffusion-controlled 
model. Two of these parameters are 
physicochemical properties associated 
with the drug and the polymer 
(Dp and Cp), whereas the surface area 
of the ring (s = 4π 2bc, where b is 
the cross-sectional radius and c the 
external radius) and the drug loading 
(A) are device-dependent.
In the reservoir vaginal ring the drug 
is located within a centralised core 
surrounded by a drug free silicone 
sheath (Figure 2b). Thus, drug 
molecules at the core/sheath interface 
must first dissociate themselves from 
the crystal lattice and dissolve into the 
surrounding silicone elastomer, before 
diffusing through the non-medicated 
sheath and finally partitioning into 
the elution medium surrounding 
the device. 
Reservoir vaginal rings were developed 
to provide zero-order release kinetics, 
where the release rate remains 
constant throughout the time the ring 
is in place (Figure 3b). They contain 
a drug-loaded core surrounded by a 
drug-free outer layer. Each ring could 
contain several cores, each containing 
a different drug, thus allowing for 
several drugs to be administered from 
the same ring. Reservoir rings are 
manufactured in several steps. A drug-
loaded core is first prepared either by 
reaction injection moulding (low drug 
concentrations, typically < 30%) or by 
extrusion (high drug concentrations, 
30–70%) of an active elastomer mix. 
The full cores may be cut into smaller 
Figure 2. (a) Schematic diagram of the cross section through a matrix 
vaginal ring. (b) Schematic diagram of the cross section through 
a reservoir vaginal ring.
Figure 3. Typical HIV microbicide release profiles for both matrix (A) and 
reservoir vaginal ring devices (B).
Equation 1. 
Q 2A C C D tp p p 0.5= -^ h6 @
Where:
Q  is the cumulative amount of 
drug released per unit area 
(mg/cm2)
A  is the drug loading per unit 
volume (mg/cm3)
Cp  is the solubility of the drug in 
the polymer phase (mg/cm3)
t  is the time
Dp  is the diffusivity of the drug in 
the polymer matrix (cm2/s).
Equation 2.
h
Q C Dp pt=
Where:
Q  is the cumulative amount of 
drug released per unit area (mg/
cm2)
t  is the time
h  is the thickness of the drug-free 
outer layer.
A. B.
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core lengths depending on the 
required release rate. The full or 
partial core(s) is then encapsulated 
with silicone elastomer in two stages 
to produce the full reservoir ring.
Changing the length and diameter 
of the core and the thickness of the 
drug-free outer layer can modify the 
rate at which the drug is released.35 
Release of the drug is achieved by 
the dissolution of the drug from 
the core into the drug-free outer 
layer then the diffusion of the drug 
through the outer layer into the 
surrounding medium. The release 
rate is dependent on the solubility 
(Cp) and the diffusion coefficent (Dp) 
of the drug in the outer layer, which 
can be represented by Equation 2.
After the recent success of the 
Centre for AIDS Programme 
of Research in South Africa’s 
(CAPRISA) clinical trial of the 
Tenofovir gel, the current goal 
of the HIV microbicide field is to 
develop an antiretroviral-releasing 
vaginal ring which should allow for 
improved adherence among women. 
Dapivirine has been successfully 
released in vitro for 28 days36 and 
71 days37 from a vaginal ring. A 
phase I trial demonstrated that a 
dapivirine vaginal ring formulation 
was safe and well tolerated and that 
release of the drug in vivo, at levels 
several orders of magnitude above 
its EC50 value, could be achieved.
38 
A phase II clinical trial of a 25 mg 
dapivirine-loaded silicone vaginal ring 
has finished recruiting volunteers 
and should begin early in 2011. 
However, the development of a 
Tenofovir-loaded vaginal ring has not 
been as straight forward. The highly 
hydrophilic character of Tenofovir 
(log P value of -2.5; water solubility 
13.4 mg/mL) is not conducive to 
release at therapeutically relevant 
rates from conventional vaginal 
ring polymers. In a bid to overcome 
this obstacle, hydrophilic, water-
swellable polyurethanes, biosoluble 
acacia gum and non-biodegradable 
hydrogels are being evaluated 
for the manufacture of Tenofovir-
releasing vaginal rings.39–40 Once an 
antiretroviral releasing ring has been 
developed and tested successfully 
in human clinical trials, the next step 
is to develop a ring that releases 
multiple HIV microbicides in order 
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